Sunshine Guojian Pharmaceutical

BioNTech’s close to $1bn acquisition of Biotheus announced earlier this month marked another big M&A deal between a Chinese biotech and a foreign firm following AstraZeneca’s roughly $1.2bn buyou

Chinese venture capital and private equity firms have rushed to pick up stakes in both preclinical- and clinical-stage biotechs for a combined CNY1.5bn ($212m) over the past month, which seemed to buc

Chinese biotechs are encountering investors who appear to have been balking at acquiring their new shares since early September, with one private equity funding scrapped, a re-financing deal reduced a

With the Nasdaq Biotechnology Index (NBI) and the closely watched XBI biotech fund down 13.2% and 18.9%, respectively, so far this year and 20.3% and 43.6% below where they were trading a year ago, ma